Specific combinations of tau phosphorylation, acetylation, and truncation mark assemblies that evade degradation and template after synaptic transfer. Altering the PTM barcode should convert seed-competent tau into transferable but weakly pathogenic tau.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["MAPT tau protein"] -->|"phosphorylation, acetylation, truncation"| B["Combined PTM barcode"]
C["CDK5, GSK3B kinases"] -->|"hyperphosphorylation"| A
D["p300, CREBBP acetyltransferases"] -->|"acetylation"| A
E["Caspases, Calpains"] -->|"truncation"| A
B -->|"specific PTM pattern"| F["Seed-competent tau assemblies"]
F -->|"resistant to clearance"| G["Evasion of proteostasis"]
G -->|"enhanced stability"| F
F -->|"packaged in vesicles"| H["Exosome release"]
H -->|"intercellular transport"| I["Trans-synaptic transfer"]
I -->|"propagation of misfolding"| J["Templating of native tau"]
J -->|"spreading of pathology"| K["Neurodegeneration"]
K -->|"neuronal loss"| L["Cognitive decline"]
M["PTM barcode modification"] -.->|"restores degradability"| G
M -.->|"reduces seed competency"| F
N["Kinase inhibitors"] -->|"target upstream PTMs"| M
O["Deacetylase activation"] -->|"alters acetylation marks"| M
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
3 citations0 with PMIDValidation: 63%2 supporting / 1 opposing
✓For(2)
No supporting evidence
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
MECH 3CLIN 0GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
No claim
Supporting
MECH
The release and…
-
2017
-
-
-
No claim
Supporting
MECH
Tau phosphoryla…
-
-
-
-
-
No claim
Opposing
MECH
-
-
-
-
-
-
Legacy Card View — expandable citation cards
✓ Supporting Evidence
2
No claim
The release and trans-synaptic transmission of Tau via exosomes · 2017
No claim
Tau phosphorylation and truncation literature
✗ Opposing Evidence
1
No claim
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Seed-competent tau is likely defined by a compact beta-rich conformer exposing repeat-domain surfaces, a permissive PTM barcode, and packaging into vesicles or synaptic compartments that protect it from degradation during transfer.
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Uptake is not seeding. The decisive experiment must compare matched tau species that enter neurons equally but differ in templating kinetics, persistence, and downstream neurotoxicity.
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Clinically, the best product concept is a conformation- or PTM-selective antibody paired with CSF seed amplification or tau-PET enrichment. Broad tau lowering risks interfering with normal microtubule biology.
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Ranked synthesis: conformer exposure is primary, PTM barcode is the strongest modulator, and vesicle context explains why some transferable tau remains non-pathogenic.